Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Olson

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
The Lancet. Oncology|June 15, 2016
Paediatric extracranial germ-cell tumoursFurqan Shaikh, Matthew J Murray, James F Amatruda, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2018
Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International ConsortiumA Lindsay Frazier, Sara Stoneham, Carlos Rodriguez-Galindo, et al.
Pediatric Blood & Cancer|December 30, 2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 studyBryan J Dicken, Deborah F Billmire, Mark Krailo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology GroupFurqan Shaikh, John W Cullen, Thomas A Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882Barbara Cushing, Roger Giller, John W Cullen, et al.
Cancer|October 21, 2015
Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International CollaborativeFarzana Pashankar, Juliet P Hale, Ha Dang, et al.
Gynecologic Oncology|June 10, 2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?Rachana Shah, Caihong Xia, Mark Krailo, et al.
Cancers|March 12, 2020
Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell BiologyGabriele Calaminus, Dominik T Schneider, Dietrich von Schweinitz, et al.
Blood|December 15, 2005
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpuraCarolyn M Bennett, Zora R Rogers, Daniel D Kinnamon, et al.
Pediatric Blood & Cancer|October 22, 2008
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximabBrigitta U Mueller, Carolyn M Bennett, Henry A Feldman, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|June 15, 2016
Paediatric extracranial germ-cell tumoursFurqan Shaikh, Matthew J Murray, James F Amatruda, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2018
Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International ConsortiumA Lindsay Frazier, Sara Stoneham, Carlos Rodriguez-Galindo, et al.
Pediatric Blood & Cancer|December 30, 2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 studyBryan J Dicken, Deborah F Billmire, Mark Krailo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology GroupFurqan Shaikh, John W Cullen, Thomas A Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882Barbara Cushing, Roger Giller, John W Cullen, et al.
Cancer|October 21, 2015
Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International CollaborativeFarzana Pashankar, Juliet P Hale, Ha Dang, et al.
Gynecologic Oncology|June 10, 2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?Rachana Shah, Caihong Xia, Mark Krailo, et al.
Cancers|March 12, 2020
Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell BiologyGabriele Calaminus, Dominik T Schneider, Dietrich von Schweinitz, et al.
Blood|December 15, 2005
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpuraCarolyn M Bennett, Zora R Rogers, Daniel D Kinnamon, et al.
Pediatric Blood & Cancer|October 22, 2008
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximabBrigitta U Mueller, Carolyn M Bennett, Henry A Feldman, et al.
Pageof 5